CHARACTERIZATION OF PLUTONIUM CONTAMINATED SOILS FROM THE NEVADA TEST SITE IN SUPPORT OF EVALUATION OF REMEDIATION TECHNOLOGIES

ABSTRACT The removal of plutonium from Nevada Test Site (NTS) area soils has previously been attempted using various combinations of attrition scrubbing, size classification, gravitybased separation, flotation, air flotation, segmented gate, bioremediation, magnetic separation and vitrification. Results were less than encouraging, but the processes were not fully optimized. To support additional vendor treatability studies soil from the Clean Slate II site (located on the Tonopah Test Range, north of the NTS) were characterized and tested. These particular soils from the NTS are contaminated primarily with plutonium-239/240 and Am-241. Soils were characterized for Pu-239/240, Am-241 and gross alpha. In addition, wet sieving and the subsequent characterization were performed on soils before and after attrition scrubbing to determine the particle size distribution and the distribution of Pu-239/240 and gross alpha as a function of particle size. Sequential extraction was performed on untreated soil to provide information about how tightly bound the plutonium was to the soil. Magnetic separation was performed to determine if this could be useful as part of a treatment approach. The results indicate that about a 40% volume reduction of contaminated soil should be achievable by removing the >300 um size fraction of the soil. Attrition scrubbing does not effect particle size distribution, but does result in a slight shift of plutonium distribution to the fines. As such, attrition scrubbing may be able to slightly increase the ability to separate plutonium-contaminated particles from clean soil. This could add another 5-10% to the mass of the clean soil, bringing the total clean soil to 45-50%. Additional testing would be needed to determine the value of using attrition scrubbing as well as screening the soil through a sieve size slightly smaller than 300 um. Since only attrition scrubbing and wet sieving would be needed to attain this, it would be good to conduct this investigation. Magnetic separation did not work well. The sequential extraction studies indicated that a significant amount of plutonium was soluble in the "organic" and "resistant" extracts. As such chemical extraction based on these or similar extractants should also be considered as a possible treatment approach. WM '03 Conference, February 23-27, 2003 , Tucson, AZ 2 INTRODUCTION The removal of plutonium from Nevada Test Site (NTS) area soils has previously been attempted using various combinations of attrition, scrubbing, size classification, gravitybased separation, flotation, air flotation, segmented gate, bioremediation, magnetic separation, and vitrification (1). Results were less than encouraging, but the processes were not fully optimized. There is an opportunity for significant improvement through the utilization of more in depth studies

EVALUATION OF REMEDIATION TECHNOLOGIES FOR PLUTONIUM CONTAMINATED SOIL

Soils contaminated with radionuclides are an environmental concern at most Department of Energy (DOE) sites. Clean up efforts at many of these sites are ongoing using conventional remediation techniques. These remediation techniques are often expensive and may not achieve desired soil volume reduction. Several studies using alternative remediation techniques have been performed on plutonium-contaminated soils from the Nevada Test Site. Results to date exhibit less than encouraging results, but these processes were often not fully optimized, and other approaches are possible. Clemson University and teaming partner Waste Policy Institute, through a cooperative agreement with the National Environmental Technologies Laboratory, are assisting the Nevada Test Site (NTS) in re-evaluating technologies that have the potential of reducing the volume of plutonium contaminated soil. This efforts includes (1) a through literature review and summary of (a) NTS soil characterization and (b) volume reduction treatment technologies applied to plutonium-contaminated NTS soils, (2) an interactive workshop for vendors, representatives from DOE sites and end-users, and (3) bench scale demonstration of applicable vendor technologies at the Clemson Environmental Technologies Laboratory

Phase II Randomized, Double-Masked, Vehicle-Controlled Trial of Recombinant Human Nerve Growth Factor for Neurotrophic Keratitis

Purpose: To evaluate the safety and efficacy of topical recombinant human nerve growth factor (rhNGF) for treating moderate-to-severe neurotrophic keratitis (NK), a rare degenerative corneal disease resulting from impaired corneal innervation. Design: Phase II multicenter, randomized, double-masked, vehicle-controlled trial. Participants: Patients with stage 2 (moderate) or stage 3 (severe) NK in 1 eye. Methods: The REPARO phase II study assessed safety and efficacy in 156 patients randomized 1:1:1 to rhNGF 10 \u3bcg/ml, 20 \u3bcg/ml, or vehicle. Treatment was administered 6 drops per day for 8 weeks. Patients then entered a 48- or 56-week follow-up period. Safety was assessed in all patients who received study treatment, whereas efficacy was by intention to treat. Main Outcome Measures: Corneal healing (defined as <0.5-mm maximum diameter of fluorescein staining in the lesion area) was assessed by masked central readers at week 4 (primary efficacy end point) and week 8 (key secondary end point) of controlled treatment. Corneal healing was reassessed post hoc by masked central readers using a more conservative measure (0-mm staining in the lesion area and no other persistent staining). Results: At week 4 (primary end point), 19.6% of vehicle-treated patients achieved corneal healing (<0.5-mm lesion staining) versus 54.9% receiving rhNGF 10 \u3bcg/ml (+35.3%; 97.06% confidence interval [CI], 15.88\u201354.71; P < 0.001) and 58.0% receiving rhNGF 20 \u3bcg/ml (+38.4%; 97.06% CI, 18.96\u201357.83; P < 0.001). At week 8 (key secondary end point), 43.1% of vehicle-treated patients achieved less than 0.5-mm lesion staining versus 74.5% receiving rhNGF 10 \u3bcg/ml (+31.4%; 97.06% CI, 11.25\u201351.49; P = 0.001) and 74.0% receiving rhNGF 20 \u3bcg/ml (+30.9%; 97.06% CI, 10.60\u201351.13; P = 0.002). Post hoc analysis of corneal healing by the more conservative measure (0-mm lesion staining and no other persistent staining) maintained statistically significant differences between rhNGF and vehicle at weeks 4 and 8. More than 96% of patients who healed after controlled rhNGF treatment remained recurrence free during follow-up. Treatment with rhNGF was well tolerated; adverse effects were mostly local, mild, and transient. Conclusions: Topical rhNGF is safe and more effective than vehicle in promoting healing of moderate-to-severe NK

Nicotinic acetylcholine receptor subunit variants are associated with blood pressure; findings in the Old Order Amish and replication in the Framingham Heart Study

<p>Abstract</p> <p>Background</p> <p>Systemic blood pressure, influenced by both genetic and environmental factors, is regulated via sympathetic nerve activity. We assessed the role of genetic variation in three subunits of the neuromuscular nicotinic acetylcholine receptor positioned on chromosome 2q, a region showing replicated evidence of linkage to blood pressure.</p> <p>Methods</p> <p>We sequenced <it>CHRNA1</it>, <it>CHRND </it>and <it>CHRNG </it>in 24 Amish subjects from the Amish Family Diabetes Study (AFDS) and identified 20 variants. We then performed association analysis of non-redundant variants (n = 12) in the complete AFDS cohort of 1,189 individuals, and followed by genotyping blood pressure-associated variants (n = 5) in a replication sample of 1,759 individuals from the Framingham Heart Study (FHS).</p> <p>Results</p> <p>The minor allele of a synonymous coding SNP, rs2099489 in <it>CHRNG</it>, was associated with higher systolic blood pressure in both the Amish (p = 0.0009) and FHS populations (p = 0.009) (minor allele frequency = 0.20 in both populations).</p> <p>Conclusion</p> <p><it>CHRNG </it>is currently thought to be expressed only during fetal development. These findings support the Barker hypothesis, that fetal genotype and intra-uterine environment influence susceptibility to chronic diseases later in life. Additional studies of this variant in other populations, as well as the effect of this variant on acetylcholine receptor expression and function, are needed to further elucidate its potential role in the regulation of blood pressure. This study suggests for the first time in humans, a possible role for genetic variation in the neuromuscular nicotinic acetylcholine receptor, particularly the gamma subunit, in systolic blood pressure regulation.</p

Healthy ageing and depletion of intracellular glutathione influences T cell membrane thioredoxin-1 levels and cytokine secretion

Background: During ageing an altered redox balance has been observed in both intracellular and extracellular compartments, primarily due to glutathione depletion and metabolic stress. Maintaining redox homeostasis is important for controlling proliferation and apoptosis in response to specific stimuli for a variety of cells. For T cells, the ability to generate specific response to antigen is dependent on the oxidation state of cell surface and cytoplasmic protein-thiols. Intracellular thiols are maintained in their reduced state by a network of redox regulating peptides, proteins and enzymes such as glutathione, thioredoxins and thioredoxin reductase. Here we have investigated whether any relationship exists between age and secreted or cell surface thioredoxin-1, intracellular glutathione concentration and T cell surface thioredoxin 1 (Trx-1) and how this is related to interleukin (IL)-2 production.Results: Healthy older adults have reduced lymphocyte surface expression and lower circulating plasma Trx-1 concentrations. Using buthionine sulfoximine to deplete intracellular glutathione in Jurkat T cells we show that cell surface Trx-1 is lowered, secretion of Trx-1 is decreased and the response to the lectin phytohaemagglutinin measured as IL-2 production is also affected. These effects are recapitulated by another glutathione depleting agent, diethylmaleate.Conclusion: Together these data suggest that a relationship exists between the intracellular redox compartment and Trx-1 proteins. Loss of lymphocyte surface Trx-1 may be a useful biomarker of healthy ageing. © 2013 Carilho Torrao et al.; licensee Chemistry Central Ltd

Lipid (per) oxidation in mitochondria:an emerging target in the ageing process?

Lipids are essential for physiological processes such as maintaining membrane integrity, providing a source of energy and acting as signalling molecules to control processes including cell proliferation, metabolism, inflammation and apoptosis. Disruption of lipid homeostasis can promote pathological changes that contribute towards biological ageing and age-related diseases. Several age-related diseases have been associated with altered lipid metabolism and an elevation in highly damaging lipid peroxidation products; the latter has been ascribed, at least in part, to mitochondrial dysfunction and elevated ROS formation. In addition, senescent cells, which are known to contribute significantly to age-related pathologies, are also associated with impaired mitochondrial function and changes in lipid metabolism. Therapeutic targeting of dysfunctional mitochondrial and pathological lipid metabolism is an emerging strategy for alleviating their negative impact during ageing and the progression to age-related diseases. Such therapies could include the use of drugs that prevent mitochondrial uncoupling, inhibit inflammatory lipid synthesis, modulate lipid transport or storage, reduce mitochondrial oxidative stress and eliminate senescent cells from tissues. In this review, we provide an overview of lipid structure and function, with emphasis on mitochondrial lipids and their potential for therapeutic targeting during ageing and age-related disease

Cholinergic receptor pathways involved in apoptosis, cell proliferation and neuronal differentiation

Acetylcholine (ACh) has been shown to modulate neuronal differentiation during early development. Both muscarinic and nicotinic acetylcholine receptors (AChRs) regulate a wide variety of physiological responses, including apoptosis, cellular proliferation and neuronal differentiation. However, the intracellular mechanisms underlying these effects of AChR signaling are not fully understood. It is known that activation of AChRs increase cellular proliferation and neurogenesis and that regulation of intracellular calcium through AChRs may underlie the many functions of ACh. Intriguingly, activation of diverse signaling molecules such as Ras-mitogen-activated protein kinase, phosphatidylinositol 3-kinase-Akt, protein kinase C and c-Src is modulated by AChRs. Here we discuss the roles of ACh in neuronal differentiation, cell proliferation and apoptosis. We also discuss the pathways involved in these processes, as well as the effects of novel endogenous AChRs agonists and strategies to enhance neuronal-differentiation of stem and neural progenitor cells. Further understanding of the intracellular mechanisms underlying AChR signaling may provide insights for novel therapeutic strategies, as abnormal AChR activity is present in many diseases